Skip to main content
Log in

Prolonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Aims

To investigate the benefits and the risks of a prolonged duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation.

Methods and results

Electronic scientific databases were searched for randomized trials investigating the clinical impact of prolonged versus control DAPT duration in patients receiving a PCI with DES implantation. Primary outcomes were the incidence of stent thrombosis (ST), major bleeding and death. Secondary outcomes were the incidence of cardiac death, myocardial infarction (MI) and cerebrovascular event (CVE). The main analysis evaluated the primary outcomes by including events that occurred whereas therapies in the treatment groups actually differed. Events occurred at the longest follow-up available for each included trial contributed to risk estimates in a separate analysis. Odds ratio (95 % confidence interval) served as summary statistic. Ten trials totaling 32,194 participants were included in the meta-analysis. Median DAPT duration was 15 (12–24) versus 6 (6–12) months for the prolonged and control DAPT groups, respectively. After a median follow-up of 19.5 months, a prolonged versus control DAPT reduces the risk of ST [0.50 (0.29–0.85), P = 0.01] and MI [0.55 (0.45–0.67), P < 0.001], at the expense of higher risk of major bleeding [1.67 (1.31–2.13), P < 0.001] and death [1.25 (1.02–1.53), P = 0.03]. A prolonged versus control DAPT does not influence the risk of cardiac death [1.08 (0.82–1.44), P = 0.74] or CVE [0.84 (0.57–1.24), P = 0.39].

Conclusions

Prolonging the duration of dual antiplatelet therapy in patients undergoing PCI with DES implantation reduces the risk of stent thrombosis and myocardial infarction, but does result in an increased risk of major bleeding and death.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A (2014) The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35(37):2541–2619

    Article  PubMed  Google Scholar 

  2. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH (2011) ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58(24):e44–e122

    Article  PubMed  Google Scholar 

  3. Cassese S, Byrne RA, Tada T, King LA, Kastrati A (2012) Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. Eur Heart J 33(24):3078–3087

    Article  CAS  PubMed  Google Scholar 

  4. El-Hayek G, Messerli F, Bangalore S, Hong MK, Herzog E, Benjo A, Tamis-Holland JE (2014) Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents. Am J Cardiol 114(2):236–242

    Article  CAS  PubMed  Google Scholar 

  5. Bulluck H, Kwok CS, Ryding AD, Loke YK (2014) Safety of short-term dual antiplatelet therapy after drug-eluting stents: an updated meta-analysis with direct and adjusted indirect comparison of randomized control trials. Int J Cardiol 181C:331–339

    Google Scholar 

  6. Collet JP, Silvain J, Barthelemy O, Range G, Cayla G, Van Belle E, Cuisset T, Elhadad S, Schiele F, Lhoest N, Ohlmann P, Carrie D, Rousseau H, Aubry P, Monsegu J, Sabouret P, O’Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Beygui F, Vicaut E, Montalescot G (2014) Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 384(9954):1577–1585

    Article  CAS  PubMed  Google Scholar 

  7. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK (2014) Ver Lee P, Rinaldi MJ, Massaro JM. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371(23):2155–2166

    Article  PubMed Central  PubMed  Google Scholar 

  8. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB (2014) American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation 129(3):399–410

    Article  PubMed  Google Scholar 

  9. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560

    Article  PubMed Central  PubMed  Google Scholar 

  10. Juni P, Witschi A, Bloch R, Egger M (1999) The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282(11):1054–1060

    Article  CAS  PubMed  Google Scholar 

  11. Sterne JA, Egger M, Smith GD (2001) Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 323(7304):101–105

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269. W64

  13. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS (2012) Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 125(3):505–513

    Article  CAS  PubMed  Google Scholar 

  14. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB 3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusmao M, Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL (2013) Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310(23):2510–2522

    CAS  PubMed  Google Scholar 

  15. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park BE, Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y (2012) A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 60(15):1340–1348

    Article  CAS  PubMed  Google Scholar 

  16. Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N, Oteo Dominguez JF, Steffanon L, Tarantini G, Presbitero P, Menozzi A, Pucci E, Mauri J, Cesana BM, Giustino G, Sardella G (2014) Second-Generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the security randomized clinical trial. J Am Coll Cardiol 64(20):2086–2097

    Article  CAS  PubMed  Google Scholar 

  17. Lee CW, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Han S, Lee SG, Seong IW, Rha SW, Jeong MH, Lim DS, Yoon JH, Hur SH, Choi YS, Yang JY, Lee NH, Kim HS, Lee BK, Kim KS, Lee SU, Chae JK, Cheong SS, Suh IW, Park HS, Nah DY, Jeon DS, Seung KB, Lee K, Jang JS, Park SJ (2014) Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation 129(3):304–312

    Article  CAS  PubMed  Google Scholar 

  18. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Tebaldi M, Fuca G, Kubbajeh M, Cangiano E, Minarelli M, Scalone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R (2012) Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 125(16):2015–2026

    Article  CAS  PubMed  Google Scholar 

  19. Gilard M, Barragan P, Noryani AA, Noor HA, Majwal T, Hovasse T, Castellant P, Schneeberger M, Maillard L, Bressolette EE, Wojcik J, Delarche N, Blanchard D, Jouve B, Ormezzano O, Paganelli F, Levy G, Sainsous J, Carrie D, Furber A, Berland J, Darremont O, Le Breton H, Lyuycx-Bore A, Gommeaux A, Cassat C, Kermarrec A, Cazaux P, Druelles P, Dauphin R, Armengaud J, Dupouy P, Champagnac D, Ohlmann P, Endresen KK, Benamer H, Kiss RG, Ungi I, Boschat JJ, Morice MC (2015) Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial. J Am Coll Cardiol 65(8):777–786

    Article  CAS  PubMed  Google Scholar 

  20. Schulz-Schüpke S, Byrne RA, ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, Tölg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Mudra M, von Hodenberg H, Wöhrle J, Angiolillo DJ, von Merzljak B, Rifatov N, Kufner S, Morath T, Feuchtenberger A, Ibrahim T, Janssen PW, Valina C, Li Y, Desmet W, Abdel-Wahab M, Tiroch K, Hengstenberg C, Bernlochner I, Fischer M, Schunkert H, Laugwitz K-L, Schömig A, Mehilli J, Kastrati A (2015) ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. doi:10.1093/eurheartj/ehu523

    PubMed  Google Scholar 

  21. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van, Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW (2007) Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115(17):2344–2351

    Article  PubMed  Google Scholar 

  22. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML (1988) Thrombolysis in Myocardial Infarction (TIMI) Trial–phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11(1):1–11

    Article  CAS  PubMed  Google Scholar 

  23. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123(23):2736–2747

    Article  PubMed  Google Scholar 

  24. Pilgrim T, Windecker S (2014) Antiplatelet therapy for secondary prevention of coronary artery disease. Heart 100(22):1750–1756

    Article  CAS  PubMed  Google Scholar 

  25. Tada T, Byrne RA, Simunovic I, King LA, Cassese S, Joner M, Fusaro M, Schneider S, Schulz S, Ibrahim T, Ott I, Massberg S, Laugwitz KL, Kastrati A (2013) Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv 6(12):1267–1274

    Article  PubMed  Google Scholar 

  26. Kang SH, Park KW, Kang DY, Lim WH, Park KT, Han JK, Kang HJ, Koo BK, Oh BH, Park YB, Kandzari DE, Cohen DJ, Hwang SS, Kim HS (2014) Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. Eur Heart J 35(17):1147–1158

    Article  CAS  PubMed  Google Scholar 

  27. Kastrati A, Byrne RA, Schulz S (2011) Will we ever know the optimal duration of dual antiplatelet therapy after drug-eluting stent implantation? JACC Cardiovasc Interv 4(10):1129–1132

    Article  PubMed  Google Scholar 

  28. Schulz S, Schuster T, Mehilli J, Byrne RA, Ellert J, Massberg S, Goedel J, Bruskina O, Ulm K, Schomig A, Kastrati A (2009) Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J 30(22):2714–2721

    Article  CAS  PubMed  Google Scholar 

  29. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW (2011) A prospective natural-history study of coronary atherosclerosis. N Engl J Med 364(3):226–235

    Article  CAS  PubMed  Google Scholar 

  30. Nammas W, Ligthart JM, Karanasos A, Witberg KT, Regar E (2013) Optical coherence tomography for evaluation of coronary stents in vivo. Expert Rev Cardiovasc Ther 11(5):577–588

    Article  CAS  PubMed  Google Scholar 

  31. Otsuka F, Vorpahl M, Nakano M, Foerst J, Newell JB, Sakakura K, Kutys R, Ladich E, Finn AV, Kolodgie FD, Virmani R (2014) Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation 129(2):211–223

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. de Waha A, Cassese S, Park DW, Burzotta F, Byrne RA, Tada T, King LA, Park SJ, Schomig A, Kastrati A (2012) Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. Clin Res Cardiol 101(6):461–467

    Article  CAS  PubMed  Google Scholar 

  33. Schulz S, Kastrati A (2013) Individualization of dual antiplatelet therapy duration after drug-eluting stent implantation: paradigm and reality. Eur Heart J 34(12):872–874

    Article  PubMed  Google Scholar 

  34. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schomig A, Kastrati A (2008) Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 51(7):690–697

    Article  PubMed  Google Scholar 

  35. Elmariah S, Mauri L, Doros G, Galper BZ, O’Neill KE, Steg PG, Kereiakes DJ, Yeh RW (2014) Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet

  36. Spoon DB, Psaltis PJ, Singh M, Holmes DR Jr, Gersh BJ, Rihal CS, Lennon RJ, Moussa ID, Simari RD, Gulati R (2014) Trends in cause of death after percutaneous coronary intervention. Circulation 129(12):1286–1294

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no potential conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Salvatore Cassese.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 1440 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cassese, S., Byrne, R.A., Ndrepepa, G. et al. Prolonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials. Clin Res Cardiol 104, 887–901 (2015). https://doi.org/10.1007/s00392-015-0860-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-015-0860-1

Keywords

Navigation